
Androgenetic Alopecia - Pipeline Insight, 2024
Description
Androgenetic Alopecia - Pipeline Insight, 2024
DelveInsight’s, “Androgenetic Alopecia – Pipeline Insight, 2024,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Androgenetic Alopecia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Androgenetic Alopecia: Overview
Androgenetic alopecia is a common form of hair loss in both men and women. In men, this condition is also known as male-pattern baldness. Hair is lost in a well-defined pattern, beginning above both temples. Over time, the hairline recedes to form a characteristic ""M"" shape. Pattern or androgenetic alopecia is a genetically predetermined disorder due to excessive response to androgens which affects up to 50% of males and females. It is characterized by progressive loss of terminal hair of the scalp any time after puberty, in a characteristic distribution in both males and females. In males, hair loss is most prominent in the vertex and frontotemporal regions, while in women the frontal hairline is typically spared with diffuse apical hair loss noted as a wider anterior part of the hair. Androgenetic alopecia patients have higher production of dihydrotestosterone, and higher levels of 5 alpha-reductase and androgen receptors in balding scalp. Androgenetic alopecia is usually diagnosed clinically with a history of gradual onset, occurring after puberty, and often but not necessarily, a family history of baldness. There are two FDA approved drugs for pattern baldness: topical minoxidil and finasteride, both of which require at least a 4- to 6-month trial before noticing improvement and must be used indefinitely to maintain a response.
""Androgenetic Alopecia - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Androgenetic Alopecia pipeline landscape is provided which includes the disease overview and Androgenetic Alopecia treatment guidelines. The assessment part of the report embraces, in depth Androgenetic Alopecia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Androgenetic Alopecia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Androgenetic Alopecia R&D. The therapies under development are focused on novel approaches to treat/improve Androgenetic Alopecia.
This segment of the Androgenetic Alopecia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Androgenetic Alopecia Emerging Drugs
- KX-826: Kintor Pharma
- Clascoterone: Cassiopea
Further product details are provided in the report……..
Androgenetic Alopecia: Therapeutic Assessment
This segment of the report provides insights about the different Androgenetic Alopecia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Androgenetic Alopecia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Androgenetic Alopecia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Androgenetic Alopecia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Androgenetic Alopecia drugs.
Androgenetic Alopecia Report Insights
- Androgenetic Alopecia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Androgenetic Alopecia drugs?
- How many Androgenetic Alopecia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Androgenetic Alopecia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Androgenetic Alopecia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Androgenetic Alopecia and their status?
- What are the key designations that have been granted to the emerging drugs?
Table of Contents
50 Pages
- Introduction
- Executive Summary
- Androgenetic Alopecia: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- KX-826: Kintor Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early stage products (Phase I)
- Comparative Analysis
- GT20029: Kintor Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Androgenetic Alopecia Key Companies
- Androgenetic Alopecia Key Products
- Androgenetic Alopecia- Unmet Needs
- Androgenetic Alopecia- Market Drivers and Barriers
- Androgenetic Alopecia- Future Perspectives and Conclusion
- Androgenetic Alopecia Analyst Views
- Androgenetic Alopecia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.